From the FDA Drug Label
Manufactured by: Pharmathen International S. A. Industrial Park Sapes, Rodopi Prefecture, Block No 5, Rodopi 69300, Greece Manufactured by: Pharmathen International S.A., Rodopi, Greece The drug lanreotide is manufactured in Greece by Pharmathen International S.A. 1 1
From the Research
Lanreotide is available in Greece, marketed under the brand name Somatuline Autogel, and is prescribed for conditions such as acromegaly and neuroendocrine tumors. The medication is typically administered as a deep subcutaneous injection every 28 days, with dosages ranging from 60 mg to 120 mg depending on the specific condition and patient response. Patients in Greece can access this medication through the Greek healthcare system with appropriate prescription from an endocrinologist or oncologist. Lanreotide works as a somatostatin analog that inhibits the release of growth hormone and various hormones of the digestive system, making it effective for treating conditions characterized by excessive hormone production.
- The medication is generally covered by Greek public health insurance (EOPYY) for approved indications, though specific coverage details may vary based on individual circumstances and current healthcare policies 2.
- Lanreotide has been shown to be effective in treating acromegaly and neuroendocrine tumors, with studies demonstrating its ability to reduce hormone secretion and tumor growth 3, 4.
- The most recent and highest quality study on lanreotide, published in 2016, highlights its role in treating gastroenteropancreatic neuroendocrine tumors, with significant prolongation of progression-free survival in metastatic patients 2.
- Overall, lanreotide is a valuable treatment option for patients in Greece with acromegaly and neuroendocrine tumors, offering effective management of symptoms and tumor growth.